The mission of the company is to discover and develop innovative therapies for the prevention and treatment of ischemia-reperfusion injury (IRI).  The interruption and subsequent restoration of circulation causes varying amounts of IRI which occurs in two phases.  The first phase (immediate or very early) is associated with increased vascular permeability and edema.  In the second phase (delayed, hours later), a network of signaling pathways initiates gene transcription, which leads to inflammation (Figure 1).  IRI causes substantial organ dysfunction and cell death.  IRI is a significant feature of many clinical events, such as organ transplantation, stroke, cardiopulmonary bypass (CPB) and myocardial infarction (MI).  There are currently no effective therapies to prevent or treat IRI.  Many potential therapies have focused on the consequences of IRI but have ignored its causes.


Figure 1. Stages of Ischemia-Reperfusion Injury (IRI)

Contact Information

Tom Egan
Lynn Egan
Nick Ellis
Perry Genova 


Note: This site is currently under development.